newsfilter
← Latest News
GlobeNewswire·

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

SER
  • Serina Therapeutics completed sentinel dosing in Cohort 1 of its Phase 1b registrational trial for SER-252 in advanced Parkinson's disease patients.
  • The independent Data Safety Monitoring Committee reviewed 72-hour safety observations & recommended continued dosing for the remainder of Cohort 1.
  • Additional patient dosing in Cohort 1 is now underway at sites in the US & Australia.
  • The company expects to complete Cohort 1 enrollment & dosing ahead of the previously disclosed end-of-third-quarter-2026 guidance.
  • SER-252 is an investigational apomorphine therapy utilizing the POZ Platform to provide sustained subcutaneous exposure & continuous dopaminergic stimulation.
  • The Phase 1b trial is a randomized, double-blind, placebo-controlled study evaluating safety, tolerability, pharmacokinetics, & exploratory efficacy measures like MDS-UPDRS motor scores.
  • Dose escalation is overseen by a Safety Monitoring Committee, with plans to expand to sites in South Korea & Taiwan in subsequent cohorts.
  • Serina's proprietary POZ Platform uses poly(2-oxazoline) polymer technology to control drug loading & release rates for improved pharmacokinetic profiles.
  • The company holds a non-exclusive license agreement with Pfizer to use its POZ polymer technology for lipid nanoparticle drug delivery formulations.
  • SER-252 aims to reduce levodopa-related motor complications in Parkinson's disease patients without causing skin reactions.